Compare Johnson & Johnson (JNJ) vs Tesla, Inc. (TSLA) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Tesla trades at $379.74, down 0.29% on the day, with bearish technical signals dominating despite recent earnings beats. The stock shows elevated valuation ratios (P/E 339, P/S 13.3) while profitability metrics have weakened, with net income margin declining to 3.95% in 2025. Recent news highlights regulatory approval for Tesla's driver assistance software in Europe and a strategic pivot toward robotics and AI amid slowing auto business growth.

Tesla faces near-term headwinds from competitive pressures and valuation concerns, but maintains strong institutional support with a $409 consensus price target. The company's expansion into autonomous driving and energy storage represents long-term growth potential, though execution risks and margin compression remain key challenges for investors.